Research Analysts Set Expectations for PLX FY2025 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Equities research analysts at Zacks Small Cap dropped their FY2025 earnings per share estimates for Protalix BioTherapeutics in a research report issued on Monday, February 3rd. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn $0.44 per share for the year, down from their prior forecast of $0.63. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. Zacks Small Cap also issued estimates for Protalix BioTherapeutics' FY2026 earnings at $0.84 EPS.

Other equities analysts have also issued research reports about the stock. HC Wainwright upped their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. StockNews.com cut shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Tuesday.

Protalix BioTherapeutics Trading Down 1.1 %

Protalix BioTherapeutics stock traded down $0.03 during mid-day trading on Wednesday, hitting $2.66. The stock had a trading volume of 565,802 shares, compared to its average volume of 606,833. The firm's 50 day moving average is $2.07 and its 200 day moving average is $1.46. The firm has a market capitalization of $195.87 million, a P/E ratio of -20.46 and a beta of 0.75. Protalix BioTherapeutics has a one year low of $0.82 and a one year high of $2.76.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC purchased a new position in Protalix BioTherapeutics in the 2nd quarter worth $37,000. Squarepoint Ops LLC raised its position in shares of Protalix BioTherapeutics by 673.3% during the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company's stock worth $161,000 after purchasing an additional 119,949 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Protalix BioTherapeutics during the 2nd quarter worth $67,000. GSA Capital Partners LLP grew its position in shares of Protalix BioTherapeutics by 8.5% in the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company's stock valued at $444,000 after purchasing an additional 33,969 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Protalix BioTherapeutics in the 3rd quarter worth $36,000. 16.53% of the stock is currently owned by institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.